Nano Antiviral Photodynamic Therapy: a Probable Biophysicochemical Management Modality in SARS-CoV-2

Introduction COVID-19 disease has shocked the world by its spread and contagiousness. At this time, there is no valid vaccine and no proven drug treatment for COVID-19 patients. Current treatments are focused on Oxygenation, Cytokine Storm management, anti-inflammatory effects, and antiviral therapy. Antiviral photodynamic therapy (aPDT) is based on the reaction between a photo-sensitive agent and a light source in the presence of oxygen which can produce oxidative and free radical agents to damage the virus' structures. Recent studies show that nanotechnology can improve aPDT's outcome. The aim of this study was to find out the potential therapeutic effects of Nano antiviral photodynamic therapy on COVID-19. Areas covered This review evaluates Nano Antiviral Photodynamic Therapy: A Probable Biophysicochemical Management Modality in SARS-CoV-2. Data were extracted from published different studies published on PUBMED, SCOPUS, and Web of Science. Expert opinion Studies indicating that aPDT and Nano-based aPDT can be useful in viral pulmonary complications like Influenza, SARS-CoV, and MERS, but there was no direct study on SARS-Cov-2. Recent studies showed that Nano-based aPDT could relate to control of the stages of viral infections. Altogether, further investigations for the application of nanomedicine in antimicrobial photodynamic inactivation are needed for COVID-19 Management.

Automated summary

This study evaluates the potential therapeutic effects of Nano antiviral photodynamic therapy on COVID-19, based on data extracted from various published studies. While studies indicate that aPDT and Nano-based aPDT may be useful in viral pulmonary complications, there is a lack of direct research on SARS-Cov-2. Recent findings suggest that Nano-based aPDT could play a role in controlling the stages of viral infections, highlighting the need for further investigation in utilizing nanomedicine for COVID-19 management.